亿帆医药股份有限公司关于公司产品纳入国家医保目录的公告

Group 1 - The company announced that some of its products have been included in the 2025 National Medical Insurance Directory, which is expected to enhance market expansion and product sales [1][2] - The innovative drug Aibegersitin α injection and the imported product Dihyaluronic Acid Sodium Injection have been renewed for inclusion, while the compound Huangdai Tablets have been adjusted to the regular national medical insurance directory [1] - The 2025 National Medical Insurance Directory will be officially implemented on January 1, 2026, with specific reimbursement standards and details to be announced by relevant government departments [2] Group 2 - The company’s subsidiary Hefei Xinzhu Biotechnology has received approval for clinical trials of the innovative macromolecule drug N-3C01 injection, targeting advanced solid tumors and non-muscle invasive bladder cancer [4][5] - N-3C01 is a recombinant IL-15/IL-15Rα fusion protein designed to activate immune cells for tumor destruction, showing promising preclinical results in activating NK cells and CD8+ T cells [6] - The approval for clinical trials indicates that the drug meets the necessary requirements for drug registration, although further steps are needed before it can be marketed [5][6]